Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RUT058-60 · RUT058

Other · developed by Pulmatrix

Phase 1/2 Most advanced trial (none active)
PULM Developer
1 Registered trials

What is RUT058-60?

RUT058-60 is an agent administered as intra-abdominal (peritoneal) lavage before closure of the abdomen at the end of surgical repair. It is studied for the prevention or treatment of deep postoperative wound infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RUT058
Drug type
Other
Therapy area
Infectious disease
Developer
Pulmatrix Inc. (PULM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02280395 Phase 1/2 Postoperative Wound Infection-deep Terminated PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Post Operative Wound InfectionPostoperative Wound Infection-deep

More from Pulmatrix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PULM page.

Follow PULM, the company behind RUT058-60

See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PULM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.